Clinical-stage cell therapy company, Chimeric Therapeutics has signed a three-year sponsored research agreement with the University of Pennsylvania in the US to support its ongoing development of gastric and colorectal cancer fighting therapies. According to Chimeric, the research will focus on further developing its cutting-edge treatments through pre-clinical studies, correlative research…



Click here to check original article.